PPAR receptor activation: Experimental studies on cardiac structure and function

Current Opinion in Investigational Drugs

Volumn 11, Issue 3, 2010, Pages 283-288

  Bishop Bailey, D ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Fatty acid; Heart; Hypertrophy; Nuclear receptor

Indexed keywords

1 PALMITOYL 2 OLEOYL SN GLYCEROL 3 PHOSPHOCHOLINE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 [4 (2 CARBAZOL 9 YLETHOXY)PHENYL) 2 ETHOXYPROPIONIC ACID; 3 CHLORO 4 [3 (7 PROPYL 3 TRIFLUOROMETHYLBENZISOXAZOL 6 YLOXY)PROPYLTHIO]PHENYLACETIC ACID; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; [4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; ALEGLITAZAR; CYTOCHROME P450 2J2; FATTY ACID; FATTY ACID SYNTHASE; FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTACYCLIN; ROSIGLITAZONE; UNCLASSIFIED DRUG;

BLOOD PRESSURE REGULATION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CIRCADIAN RHYTHM; DRUG MECHANISM; DYSLIPIDEMIA; ENDURANCE; EXERCISE; FATTY ACID METABOLISM; GENE DELETION; GENE OVEREXPRESSION; GLUCOSE METABOLISM; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE METABOLISM; HEART RATE; HEART VENTRICLE HYPERTROPHY; HUMAN; IMMUNE RESPONSE; LIPID STORAGE; NONHUMAN; OBESITY; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW;

ANIMALS; HEART; HEART DISEASES; HUMANS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 77649155778     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN et al: International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev (2006) 58(4):726-741.
2. Bishop-Bailey D: Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol (2000) 129(5):823-834.
3. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev (1999) 20(5):649-688.
4. Issemann I, Prince RA, Tugwood JD, Green S: The peroxisome proliferator-activated receptor:retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J Mol Endocrinol (1993) 11(1):37-47.
5. IJpenberg A, Jeannin E, Wahli W, Desvergne B: Polarity and specific sequence requirements of peroxisome proliferator-activated receptor (PPAR)/retinoid X receptor heterodimer binding to DNA. A functional analysis of the malic enzyme gene PPAR response element. J Biol Chem (1997) 272(32):20108-20117.
6. Gervois P, Chopin-Delannoy S, Fadel A, Dubois G, Kosykh V, Fruchart JC, Najib J, Laudet V, Staels B: Fibrates increase human REVERBα expression in liver via a novel peroxisome proliferatoractivated receptor response element. Mol Endocrinol (1999) 13(3):400-409.
7. Bishop-Bailey D: The platelet as a model system for the acute actions of nuclear receptors. Steroids (2009):doi:10.1016/j. steroids.2009.09.005.
8. Gulick T, Cresci S, Caira T, Moore DD, Kelly DP: The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA (1994) 91(23):11012-11016. (Pubitemid 24349615)
9. Keller H, Dreyer C, Medin J, Mahfoudi A, Ozato K, Wahli W: Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA (1993) 90(6):2160-2164.
10. Keller H, Mahfoudi A, Dreyer C, Hihi AK, Medin J, Ozato K, Wahli W: Peroxisome proliferator-activated receptors and lipid metabolism. Ann NY Acad Sci (1993) 684:157-173.
11. Fredenrich A, Grimaldi PA: PPARα: An uncompletely known nuclear receptor. Diabetes Metab (2005) 31(1):23-27.
12. Barish GD, Narkar VA, Evans RM: PPARα: A dagger in the heart of the metabolic syndrome. J Clin Invest (2006) 116(3):590-597.
13. Bishop-Bailey D, Bystrom J: Emerging roles of peroxisome proliferator-activated receptor-β/δ in inflammation. Pharmacol Ther (2009) 124(2):141-150.
14. Chinetti G, Fruchart JC, Staels B: Peroxisome proliferatoractivated receptors and inflammation: From basic science to clinical applications. Int J Obes Relat Metab Disord (2003) 27(Suppl 3):S41-S45.
15. Grommes C, Landreth GE, Heneka MT: Antineoplastic effects of peroxisome proliferator-activated receptor δ agonists. Lancet Oncol (2004) 5(7):419-429.
16. Neubauer S: The failing heart - An engine out of fuel. N Engl J Med (2007) 356(11):1140-1151.
17. Boudina S, Abel ED: Diabetic cardiomyopathy revisited. Circulation (2007) 115(25):3213-3223.
18. Holness MJ, Samsuddin S, Sugden MC: The role of PPARs in modulating cardiac metabolism in diabetes. Pharmacol Res (2009) 60(3):185-194.
19. Madrazo JA, Kelly DP: The PPAR trio: regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardiol (2008) 44(6):968-975.
20. Yang Q, Li Y: Roles of PPARs on regulating myocardial energy and lipid homeostasis. J Mol Med (2007) 85(7):697-706.
21. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W: Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J Clin Invest (1999) 103(11):1489-1498.
22. Leone TC, Weinheimer CJ, Kelly DP: A critical role for the peroxisome proliferator-activated receptor α (PPARα) in the cellular fasting response: The PPARα-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA (1999) 96(13):7473-7478.
23. Watanabe K, Fujii H, Takahashi T, Kodama M, Aizawa Y, Ohta Y, Ono T, Hasegawa G, Naito M, Nakajima T, Kamijo Y et al: Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor α associated with agedependent cardiac toxicity. J Biol Chem (2000) 275(29):22293-22299.
24. Luptak I, Balschi JA, Xing Y, Leone TC, Kelly DP, Tian R: Decreased contractile and metabolic reserve in peroxisome proliferatoractivated receptor-α-null hearts can be rescued by increasing glucose transport and utilization. Circulation (2005) 112(15):2339-2346.
25. Finck BN, Lehman JJ, Leone TC, Welch MJ, Bennett MJ, Kovacs A, Han X, Gross RW, Kozak R, Lopaschuk GD, Kelly DP: The cardiac phenotype induced by PPARα overexpression mimics that caused by diabetes mellitus. J Clin Invest (2002) 109(1):121-130.
26. Sambandam N, Morabito D, Wagg C, Finck BN, Kelly DP, Lopaschuk GD: Chronic activation of PPARα is detrimental to cardiac recovery after ischemia. Am J Physiol Heart Circ Physiol (2006) 290(1):H87-H95.
27. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, Thiemermann C: Ligands of the peroxisome proliferator-activated receptors (PPAR-γ and PPAR-α) reduce myocardial infarct size. FASEB J (2002) 16(9):1027-1040. (Pubitemid 34753509)
28. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B: Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta (2007) 1771(8):1065-1081.
29. Barak Y, Liao D, He W, Ong ES, Nelson MC, Olefsky JM, Boland R, Evans RM: Effects of peroxisome proliferator-activated receptor α on placentation, adiposity, and colorectal cancer. Proc Natl Acad Sci USA (2002) 99(1):303-308.
30. Peters JM, Lee SS, Li W, Ward JM, Gavrilova O, Everett C, Reitman ML, Hudson LD, Gonzalez FJ: Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Mol Cell Biol (2000) 20(14):5119-5128.
31. Cheng L, Ding G, Qin Q, Huang Y, Lewis W, He N, Evans RM, Schneider MD, Brako FA, Xiao Y, Chen YE et al: Cardiomyocyte-restricted peroxisome proliferator-activated receptor-δ deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med (2004) 10(11):1245-1250.
32. Li Y, Cheng L, Qin Q, Liu J, Lo WK, Brako LA, Yang Q: High-fat feeding in cardiomyocyte-restricted PPAR knockout mice leads to cardiac overexpression of lipid metabolic genes but fails to rescue cardiac phenotypes. J Mol Cell Cardiol (2009) 47(4):536-543.
33. Burkart EM, Sambandam N, Han X, Gross RW, Courtois M, Gierasch CM, Shoghi K, Welch MJ, Kelly DP: Nuclear receptors PPARβ/δ and PPARα direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest (2007) 117(12):3930-3939.
34. Wang YX, Zhang CL, Yu RT, Cho HK, Nelson MC, Bayuga-Ocampo CR, Ham J, Kang H, Evans RM: Regulation of muscle fiber type and running endurance by PPARδ. PLoS Biol (2004) 2(10):e294.
35. Narkar VA, Downes M, Yu RT, Embler E, Wang YX, Banayo E, Mihaylova MM, Nelson MC, Zou Y, Juguilon H, Kang H et al: AMPK and PPARδ agonists are exercise mimetics. Cell (2008) 134(3):405-415.
36. Wagner N, Jehl-Pietri C, Lopez P, Murdaca J, Giordano C, Schwartz C, Gounon P, Hatem SN, Grimaldi P, Wagner KD: Peroxisome proliferator-activated receptor β stimulation induces rapid cardiac growth and angiogenesis via direct activation of calcineurin. Cardiovasc Res (2009) 83(1):61-71.
37. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM: PPARγ is required for placental, cardiac, and adipose tissue development. Mol Cell (1999) 4(4):585-595.
38. Ding G, Fu M, Qin Q, Lewis W, Kim HW, Fukai T, Bacanamwo M, Chen YE, Schneider MD, Mangelsdorf DJ, Evans RM et al: Cardiac peroxisome proliferator-activated receptor γ is essential in protecting cardiomyocytes from oxidative damage. Cardiovasc Res (2007) 76(2):269-279.
39. Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM: Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-γ both induce cardiac hypertrophy in mice. Circ Res (2005) 97(4):372-379.
40. Son NH, Park TS, Yamashita H, Yokoyama M, Huggins LA, Okajima K, Homma S, Szabolcs MJ, Huang LS, Goldberg IJ: Cardiomyocyte expression of PPARα leads to cardiac dysfunction in mice. J Clin Invest (2007) 117(10):2791-2801.
41. Krishnan J, Suter M, Windak R, Krebs T, Felley A, Montessuit C, Tokarska-Schlattner M, Aasum E, Bogdanova A, Perriard E, Perriard JC et al: Activation of a HIF1α-PPARβ axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab (2009) 9(6):512-524.
42. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, Saito T, Masuda Y, Kadowaki T, Komuro I: Peroxisome proliferatoractivated receptor γ plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation (2002) 105(10):1240-1246.
43. Abdelrahman M, Sivarajah A, Thiemermann C: Beneficial effects of PPAR-γ ligands in ischemia-reperfusion injury, inflammation and shock. Cardiovasc Res (2005) 65(4):772-781.
44. Stafylas PC, Sarafidis PA, Lasaridis AN: The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Int J Cardiol (2009) 131(3):298-304.
45. Zinn A, Felson S, Fisher E, Schwartzbard A: Reassessing the cardiovascular risks and benefits of thiazolidinediones. Clin Cardiol (2008) 31(9):397-403.
46. Blasi ER, Heyen J, Hemkens M, McHarg A, Ecelbarger CM, Tiwari S: Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure and kidney in healthy Sprague- Dawley rats. PPAR Res (2009):doi:10.1155/2009/237865.
47. Chan LL, Sebert SP, Hyatt MA, Stephenson T, Budge H, Symonds ME, Gardner DS: Effect of maternal nutrient restriction from early to midgestation on cardiac function and metabolism after adolescent-onset obesity. Am J Physiol Regul Integr Comp Physiol (2009) 296(5):R1455-R1463.
48. Wang N, Yang G, Jia Z, Zhang H, Aoyagi T, Soodvilai S, Symons JD, Schnermann JB, Gonzalez FJ, Litwin SE, Yang T: Vascular PPARγ controls circadian variation in blood pressure and heart rate through Bmal1. Cell Metab (2008) 8(6):482-491.
49. Bishop-Bailey D, Wray J: Peroxisome proliferator-activated receptors: A critical review on endogenous pathways for ligand generation. Prostaglandins Other Lipid Mediat (2003) 71(1-2):1-22.
50. Wray JA, Sugden MC, Zeldin DC, Greenwood GK, Samsuddin S, Miller- Degraff L, Bradbury JA, Holness MJ, Warner TD, Bishop-Bailey D: The epoxygenases CYP2J2 activates the nuclear receptor PPARα in vitro and in vivo. PLoS One (2009) 4(10):e7421.
51. Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RR, Xu HE, Turk J, Semenkovich CF: Identification of a physiologically relevant endogenous ligand for PPARα in liver. Cell (2009) 138(3):476-488.
52. Chang F, Jaber LA, Berlie HD, O'Connell MB: Evolution of peroxisome proliferator-activated receptor agonists. Ann Pharmacother (2007) 41(6):973-983.
53. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M: Effect of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): A phase II, randomised, dose-ranging study. Lancet (2009) 374(9684):126-135.
54. Verreth W, Ganame J, Mertens A, Bernar H, Herregods MC, Holvoet P: Peroxisome proliferator-activated receptor-α, γ-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese dyslipidemic mice. Arterioscler Thromb Vasc Biol (2006) 26(4):922-928.
55. Rose M, Balakumar P, Singh M: Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats. Pharmacology (2007) 80(2-3):177-184.